CINRYZE is now the first and only Hereditary angioedema treatment approved for routine prevention in paediatrics
Zug, Switzerland – 16 March 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the European Commission (EC) has approved a label extension granting three new indications for CINRYZE® (C1 inhibitor [human]), broadening its use to children with Hereditary angiodema (HAE), a rare, genetic disorder that results in recurring attacks of edema (swelling).1 The body sites most commonly affected are mainly the extremities and abdomen.1 CINRYZE is now indicated for routine prevention of angioedema attacks in children (ages 6 years and above) with severe and recurrent attacks of HAE who are intolerant to or insufficiently protected by oral preventions treatments, or patients who are inadequately managed with repeated acute treatment.2 It is the first and only HAE treatment with this indication in paediatric patients.2 CINRYZE is also now approved for the treatment and pre-procedure prevention of angioedema attacks in children (ages 2 years and above) with HAE.2
Symptoms of HAE often present in childhood, and while attacks can occur at any age, early onset may predict a more severe disease course.3 Attacks often occur in children without a clear trigger,2 and may affect a child’s participation in school, activities, and sports, which can leave them feeling socially isolated.3,4 Less frequently, HAE can cause life-threatening attacks due to obstruction in the upper airways.5,6,7
“This paediatric label expansion demonstrates our ongoing commitment to improving the lives of patients of all ages living with HAE,” said Philip J. Vickers, Ph.D., Head of R&D, Shire. “We believe the future of HAE means preventing attacks before they happen, and are proud to now be able to offer the first long-term preventative treatment for paediatric patients. As we expand our HAE portfolio, we remain focused on innovative solutions that fulfil unmet needs for people worldwide living with this rare disease.”
CINRYZE has been approved since 2011 for these indications in adults and adolescents ages 12-17 years with HAE.2
Henrik Balle Boysen, Executive Director of HAEi stated, “Over the years we have encountered many children who suffer from frequent and severe HAE symptoms that often occur spontaneously and without warning. Despite improvements in the management of HAE in recent years, this new long-term prophylaxis indication for alleviating the frequency of HAE symptoms will be a welcome addition for families with HAE in Europe.”
CINRYZE will be available for use in paediatric patients later in 2017 throughout Member States of the European Union (EU), as well the European Economic Area (EEA) in which Shire currently has a licence in the adult and adolescent population.
HAE is a rare, genetic disorder that affects an estimated one in 50,000 people worldwide and results in recurring attacks of edema (swelling).8
Long-term prophylaxis refers to the routine use of medication to prevent episodes of angioedema, and may be considered for severely symptomatic patients with HAE.8 Management of HAE also includes on-demand treatment of swelling attacks (known as acute treatment) to minimise the consequences of the symptoms, and pre-procedure prevention, which is often used before certain surgeries and to cover other periods of high risk of attack (such as stressful times including school examinations, for example).8
Paediatric Study Results2
The efficacy of CINRYZE for the treatment and prevention of angioedema attacks in paediatric patients with HAE has been demonstrated in two open-label studies (LEVP 2006‑1 and LEVP 2006‑4) and two paediatric clinical studies (0624-203 and 0624-301).2
Two studies demonstrated the efficacy of CINRYZE for the treatment of HAE in patients ages 6-11 years. The first study (LEVP 2006-1) included 22 paediatric patients (of a total of 101 enrolled patients) who were treated for 121 acute HAE attacks. The proportion of HAE attacks achieving unequivocal relief of the defining symptom within four hours after treatment was comparable between the 22 children (ages 2-17 years) and adults enrolled in the study, with 89% and 86% of attacks achieving relief, respectively.2
The second study (0624-203) enrolled nine paediatric patients who received a single dose of CINRYZE based on their weight with children weighing between 10 and 25 kg (n=3) receiving 500 units and those weighing >25 kg receiving either 1000 units (n=3) or 1500 units (n=3). All nine (100%) subjects achieved unequivocal beginning of relief of the defining symptom within four hours following initiation of treatment with CINRYZE.2 The 1500-unit dose is not an approved dosage.
In addition, two studies demonstrated the efficacy of CINRYZE for the prevention of HAE in paediatric patients. The first study (LEVP 2006-4) included 23 paediatric patients (of a total of 146 enrolled patients) between the ages of 3 and 17 years. The children received 1000 units of CINRYZE every three to seven days, with the exception of a 3-year-old child who received 500 units every three to seven days. Prior to enrolment, the children reported a median of three HAE attacks each month. While receiving CINRYZE prophylaxis during the study, 87% of the children reported an average of one or fewer attack per month, which were comparable to those observed in adults in the study.2
The second study (0624-301) included six paediatric subjects ages 6-11 years who were randomised to twice-weekly CINRYZE dosing for 12 weeks in two treatment sequences (500/1000 units or 1000/500 units). Both doses resulted in similar reduction of attack-frequency and showed clinical benefit regarding severity, duration, and requirement for acute treatment of attacks.2
For three subjects under the age of 6 years, administration of CINRYZE (500 units or 1000 units) was associated with increases in C1 INH levels and clinical efficacy in acute treatment and prevention of attacks. Overall administration of CINRYZE was well tolerated.2
Across clinical studies, there were 61 unique paediatric subjects enrolled and exposed to over 2,500 infusions of CINRYZE (2-5 years, n=3; 6-11 years, n=32; 12-17 years, n=26). Among these children, adverse reactions with CINZYRE included headache, nausea, pyrexia, and infusion site erythema. None of these adverse reactions were severe, and none led to discontinuation of medicinal product.2 Overall, the safety and tolerability of CINRYZE were similar in children, adolescents, and adults.2
CINRYZE is the first and only C1 esterase inhibitor (C1-INH) therapy approved for routine prevention in children, adolescents, and adults with HAE. CINRYZE is also approved for acute treatment and pre-procedure prevention of angioedema attacks.2
The active substance in CINRYZE is C1-INH, which can restore functional C1-INH levels in patients with HAE.2 Patients with HAE are prone to swelling due to an underlying deficiency in C1-INH.6,9 C1-INH plays an integral role in the kinin-generating pathway and controls the production of the protein bradykinin.1,9,10,11 During a swelling attack, overproduction of bradykinin increases the permeability of blood vessels, causing fluids to “leak” into the surrounding tissue, resulting in swelling.1,13 Treatment with C1-INH raises the plasma level of C1-INH and helps regulate the production of bradykinin released during an attack.2,12,13
CINRYZE is administered intravenously and may be self-administered.2 The decision on the use of home-treatment for an individual patient should be made by the treating physician, who should ensure that appropriate training is provided and the use reviewed at intervals.2 CINRYZE therapy should be initiated under supervision of a physician experienced in the care of patients with HAE.2
For treatment of angioedema attacks in adolescents (ages 12-17 years) and adults, a dose of 1000 units of CINRYZE is given at the first sign of the onset of an attack.2 A second dose of 1000 units may be administered if the patient has not responded adequately after 60 minutes.2 For patients experiencing laryngeal attacks, or if the initiation of treatment is delayed, the second dose can be given sooner than 60 minutes.2
For routine prevention of angioedema attacks in adolescents (ages 12-17 years) and adults, 1000 units of CINRYZE every 3 or 4 days is the recommended starting dose.2 The dosing interval may need to be adjusted according to individual response.2 The continued need for regular prophylaxis with CINRYZE should be reviewed on a regular basis.2
For pre-procedure prevention of angioedema attacks in adolescents (ages 12-17 years) and adults, 1000 units of CINRYZE is given within 24 hours before a medical, dental, or surgical procedure.2
For treatment of angioedema attacks in children (ages 2-11 years) who weigh more than 25 kg, a dose of 1000 units of CINRYZE is given at the first sign of the onset of an attack.1 A second dose of 1000 units may be administered if the patient has not responded adequately after 60 minutes.1 For children who weigh between 10 to 25 kg, the starting dose is 500 units with a second dose of 500 units if the patient has not responded adequately after 60 minutes.1
For pre-procedure prevention of angioedema attacks in children (ages 2-11 years) who weigh more than 25 kg, 1000 units of CINRYZE is given within 24 hours before a medical, dental, or surgical procedure.1 For children weighing between 10 to 25 kg, the dose is 500 units.1
For routine prevention of angioedema attacks (ages 6-11 years), 500 units of CINRYZE every three or four days is the recommended starting dose (regardless of weight).1 The dosing interval may need to be adjusted according to individual response. The continued need for regular prophylaxis with CINRYZE should be reviewed on a regular basis.1
Safety and Tolerability
The only common (i.e., ≥1/100 to <1/10) adverse reaction observed following CINRYZE infusion in clinical studies was rash; descriptions of rash characteristics were non-specific, but were typically described as involving the upper extremities, chest, abdomen, or injection site.2 None of the rashes were serious, and none led to discontinuation of medicinal product.2
CINRYZE is contraindicated in patients who are hypersensitive to the active ingredients or any excipients.2
Special Warnings and Precautions for Use2
|Ian Karpemail@example.com||+1 781 482 9018|
|Robert Coatesfirstname.lastname@example.org||+44 1256 894874|
|Annabel Cowperemail@example.com||+41 44 878 6638|
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialised conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Haematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:
a further list and description of risks, uncertainties and other matters can be found in Shire’s most recent Annual Report on Form 10-K and in Shire’s subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in “ITEM 1A: Risk Factors”, and in subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire’s website.
All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the Summary of Product Characteristics for how to report adverse reactions.
1 Bork K, Davis-Lorton M. Overview of hereditary angioedema caused by C1-inhibitor deficiency: assessment and clinical management. Eur Ann Allergy Clin Immunol 2013; 45(1):7-16.
2 CINRYZE (C1 Inhibitor [human]) Summary of Product Characteristics. January 2017. Document on File at Shire.
3 Farkas H, et al. International consensus on the diagnosis and management of paediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017; 72(2):300-13.
4 Read N, et al. Patient hereditary angioedema: a survey of UK service provision and patient experience. Clin Exp Immunol 2014; 178:473-88.
5 Donaldson V, Evans R. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C1-esterase. Am J Med. 1963; 35:37-44.
6 Bork K, et al. Hereditary angioedema: New findings concerning symptoms, affected organs, and course. Am J Med 2006; 119(3):267-74.
7 Bork K. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. JAACI 2012; DOI: http://dx.doi.org/10.1016/j.jaci.2012.05.055.
8 Craig T, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ Journal 2012; 5(12):182-99.
9 Lung C, et al, Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. Allergy, Asthma Clin Immunol 1997; 99(1):134-146.
10 Nussberger J, et al. Local bradykinin generation in hereditary angioedema. Allergy Asthma Clin Immunol 1999; 104(6):1321-1322.
11 Bjorkqvist J, et al. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 2013; 109:368–374.
12 Nussberger J, et al. Plasma bradykinin in angio-edema. The Lancet 1998; 351:1693-1697.
13 Kaplan AP, Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104:193.